Food Allergy Research Is Entering a New Era
By Ilana Golant, Food Allergy Fund Founder and CEO
May 7, 2026 - For the first time, every therapeutic company presenting at the Food Allergy Fund Summit is now in human clinical trials.
This marks a major inflection point for food allergy research.
Over the years, the @Food Allergy Fund Summit has brought together some of the earliest and boldest companies working to transform the future of food allergy treatment. When many of these CEOs first presented at our Summit, their ideas were still highly experimental — promising science searching for a path to patients.
Today, those approaches are advancing through clinical development.
Companies presenting at this year's Summit included Prota Therapeutics, Moonlight Therapeutics, Ukko, and Inimmune.
That evolution reflects something much bigger than individual company progress. It signals that food allergy research has entered a new era — one where the field is moving beyond observation and management toward intervention, prevention, and potentially disease-modifying treatments.
Over the last several years, we have watched the ecosystem mature in real time:
Early-stage concepts become venture-backed platforms
Academic discoveries evolve into translational companies
Microbiome, immune modulation, AI, and precision medicine move from theory into clinical development
Collaboration between scientists, investors, physicians, and patient advocates accelerates timelines that once seemed impossible
What once felt like a fragmented space is becoming a true innovation pipeline.
At the Food Allergy Fund, we have always believed that convening the right people in one room can catalyze progress. Our Summits were designed not simply as conferences, but as launchpads for collaboration, investment, and action.
Seeing so many companies now advancing through human trials is deeply meaningful for families living with food allergies — and a powerful validation that this field is finally gaining the scientific and financial momentum it deserves.
The future of food allergy treatment is no longer hypothetical.
It is being built now.